• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长期使用质子泵抑制剂和钾竞争酸阻滞剂与多个胃神经内分泌肿瘤相关。

Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.

机构信息

Department of Gastroenterology, Kobe City Medical Center General Hospital, Japan.

Department of Pathology, Kobe City Medical Center General Hospital, Japan.

出版信息

Intern Med. 2024 Jul 15;63(14):2001-2010. doi: 10.2169/internalmedicine.2857-23. Epub 2023 Nov 27.

DOI:10.2169/internalmedicine.2857-23
PMID:38008447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11309866/
Abstract

A 52-year-old man who had been using a proton pump inhibitor (PPI) and a potassium-competitive acid blocker (P-CAB) for 14 years underwent esophagogastroduodenoscopy and was found to have three neuroendocrine tumors (NETs) in the gastric body. Following detailed examinations, parietal cell dysfunction was excluded, and the NETs did not meet the criteria for the Rindi classification types I-III. The lesions were ultimately considered to be associated with the long-term use of the PPI and P-CAB. We performed endoscopic submucosal dissection of the lesions, with no recurrence or new lesions noted after discontinuation of the PPI and P-CAB.

摘要

一位 52 岁男性，因使用质子泵抑制剂（PPI）和钾竞争性酸阻滞剂（P-CAB）长达 14 年，行食管胃十二指肠镜检查，发现胃体部有三个神经内分泌肿瘤（NET）。经过详细检查，排除壁细胞功能障碍，且 NET 不符合 Rindi 分类 I-III 型标准。最终，这些病变被认为与长期使用 PPI 和 P-CAB 有关。我们对病变进行了内镜黏膜下剥离，停用 PPI 和 P-CAB 后未见复发或新病变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/0207a046a1d8/1349-7235-63-2001-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/1ec480751d43/1349-7235-63-2001-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/6cb49dcf3478/1349-7235-63-2001-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/b40f43eaada8/1349-7235-63-2001-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/8d7fe4735841/1349-7235-63-2001-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/4aa1028448f7/1349-7235-63-2001-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/9ad18fed0cfc/1349-7235-63-2001-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/54e1b0f82e02/1349-7235-63-2001-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/1e3e5d19b02a/1349-7235-63-2001-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/a6fe8c215728/1349-7235-63-2001-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/40956c5c4680/1349-7235-63-2001-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/0207a046a1d8/1349-7235-63-2001-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/1ec480751d43/1349-7235-63-2001-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/6cb49dcf3478/1349-7235-63-2001-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/b40f43eaada8/1349-7235-63-2001-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/8d7fe4735841/1349-7235-63-2001-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/4aa1028448f7/1349-7235-63-2001-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/9ad18fed0cfc/1349-7235-63-2001-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/54e1b0f82e02/1349-7235-63-2001-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/1e3e5d19b02a/1349-7235-63-2001-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/a6fe8c215728/1349-7235-63-2001-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/40956c5c4680/1349-7235-63-2001-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a64/11309866/0207a046a1d8/1349-7235-63-2001-g011.jpg

相似文献

1
Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.长期使用质子泵抑制剂和钾竞争酸阻滞剂与多个胃神经内分泌肿瘤相关。
Intern Med. 2024 Jul 15;63(14):2001-2010. doi: 10.2169/internalmedicine.2857-23. Epub 2023 Nov 27.
2
Clinical Impact of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker for Predicting the Curability of Endoscopic Resection in Ulcerative Early Gastric Cancer.质子泵抑制剂和钾竞争酸阻滞剂对溃疡性早期胃癌内镜切除治愈率的临床影响。
Digestion. 2024;105(3):192-200. doi: 10.1159/000536617. Epub 2024 Feb 2.
3
Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?胃神经内分泌肿瘤与质子泵抑制剂：因果关系还是巧合？
Scand J Gastroenterol. 2015;50(11):1397-403. doi: 10.3109/00365521.2015.1054426. Epub 2015 Jun 10.
4
The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.von Hippel-Lindau 病中质子泵抑制剂诱导的胃神经内分泌肿瘤首例报告。
Intern Med. 2022 Sep 1;61(17):2587-2592. doi: 10.2169/internalmedicine.8701-21. Epub 2022 Feb 8.
5
Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?质子泵抑制剂的应用、高胃泌素血症与胃类癌——它们之间存在何种关联？
Int J Mol Sci. 2020 Jan 19;21(2):662. doi: 10.3390/ijms21020662.
6
A gastric neuroendocrine tumor after prolonged use of proton pump inhibitors.质子泵抑制剂长期使用后发生的胃神经内分泌肿瘤。
Rev Esp Enferm Dig. 2023 Apr;115(4):209-210. doi: 10.17235/reed.2022.9126/2022.
7
Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.长期使用质子泵抑制剂的患者发生的胃神经内分泌肿瘤为惰性肿瘤，预后良好。
Histopathology. 2020 Dec;77(6):865-876. doi: 10.1111/his.14220. Epub 2020 Sep 20.
8
Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.长期质子泵抑制剂治疗继发的高胃泌素血症对人胃黏膜肠嗜铬样（ECL）细胞肿瘤发生的影响。
Pathol Res Pract. 2020 Oct;216(10):153113. doi: 10.1016/j.prp.2020.153113. Epub 2020 Jul 13.
9
Protective effect of proton pump inhibitors and potassium competitive acid blockers against post-gastric endoscopic submucosal dissection bleeding: a single-center, propensity score-matched analysis.质子泵抑制剂和钾离子竞争性酸阻滞剂预防胃内镜黏膜下剥离术后出血的效果：一项单中心、倾向评分匹配分析。
Scand J Gastroenterol. 2021 Feb;56(2):199-204. doi: 10.1080/00365521.2020.1862906. Epub 2020 Dec 17.
10
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan.严重低镁血症与钾竞争性酸阻滞剂沃诺拉赞的长期使用相关。
Intern Med. 2022 Jan 1;61(1):119-122. doi: 10.2169/internalmedicine.7325-21. Epub 2021 Jun 26.

引用本文的文献

1
A Systematic Review of the Adverse Effects of Long-Term Proton Pump Inhibitor Use on the Gastrointestinal System in the Adult Population.长期使用质子泵抑制剂对成年人群胃肠道系统不良反应的系统评价
Cureus. 2025 Aug 20;17(8):e90606. doi: 10.7759/cureus.90606. eCollection 2025 Aug.
2
Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy.与钾离子竞争性酸阻滞剂和质子泵抑制剂治疗相关的胃黏膜变化的内镜检查结果及转归
DEN Open. 2024 Jun 24;5(1):e400. doi: 10.1002/deo2.400. eCollection 2025 Apr.

本文引用的文献

1
A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection.内镜黏膜下剥离术治疗伴壁细胞功能障碍的肠嗜铬样神经内分泌肿瘤 1 例罕见病例报告
Clin J Gastroenterol. 2022 Dec;15(6):1041-1047. doi: 10.1007/s12328-022-01704-7. Epub 2022 Sep 20.
2
The First Case of Gastric Neuroendocrine Tumors Induced by a Proton Pump Inhibitor in von Hippel-Lindau Disease.von Hippel-Lindau 病中质子泵抑制剂诱导的胃神经内分泌肿瘤首例报告。
Intern Med. 2022 Sep 1;61(17):2587-2592. doi: 10.2169/internalmedicine.8701-21. Epub 2022 Feb 8.
3
Parietal Cell Dysfunction: A Rare Cause of Gastric Neuroendocrine Neoplasm with Achlorhydria and Extreme Hypergastrinemia.
壁细胞功能障碍：一种罕见的导致胃酸缺乏和极度高胃泌素血症的胃神经内分泌肿瘤的原因。
Intern Med. 2022 Aug 15;61(16):2441-2448. doi: 10.2169/internalmedicine.8253-21. Epub 2022 Feb 1.
4
A case of enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction which was successfully treated with somatostatin analogue.一例与壁细胞功能障碍相关的肠嗜铬样细胞神经内分泌肿瘤，经生长抑素类似物成功治疗。
Clin J Gastroenterol. 2022 Apr;15(2):363-367. doi: 10.1007/s12328-021-01581-6. Epub 2022 Jan 4.
5
JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.JNETS 胃肠胰神经内分泌肿瘤临床实践指南：诊断、治疗和随访：概要。
J Gastroenterol. 2021 Nov;56(11):1033-1044. doi: 10.1007/s00535-021-01827-7. Epub 2021 Sep 29.
6
Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.42 项系统评价和荟萃分析的伞状评价：质子泵抑制剂的安全性。
Aliment Pharmacol Ther. 2021 Jul;54(2):129-143. doi: 10.1111/apt.16407. Epub 2021 Jun 11.
7
Gastric Hyperplastic Polyps Can Shrink After Discontinuation of Proton Pump Inhibitors: A Case Series Compared With Continuation of Proton Pump Inhibitors.质子泵抑制剂停药后胃增生性息肉可以缩小：一项与继续质子泵抑制剂治疗相比的病例系列研究。
J Clin Gastroenterol. 2022 Mar 1;56(3):e216-e221. doi: 10.1097/MCG.0000000000001577.
8
Disappearance of Gastric Hyperplastic Polyps after the Discontinuation of Proton Pump Inhibitor in a Patient with Liver Cirrhosis.肝硬化患者停用质子泵抑制剂后胃增生性息肉消失
Case Rep Gastroenterol. 2021 Feb 18;15(1):202-209. doi: 10.1159/000511885. eCollection 2021 Jan-Apr.
9
Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.日本胃-肠-胰神经内分泌肿瘤（GEP-NEN）患者的最新流行病学：一项基于人群的研究。
BMC Cancer. 2020 Nov 14;20(1):1104. doi: 10.1186/s12885-020-07581-y.
10
Type IV Gastric Carcinoids in the Stomach Caused by ATP4A Gene Mutations.由ATP4A基因突变引起的胃IV型胃类癌
Clin Gastroenterol Hepatol. 2020 Sep;18(10):A22. doi: 10.1016/j.cgh.2019.07.063. Epub 2019 Aug 8.